A pair of former GlaxoSmithKline ($GSK) scientists specializing in neurosciences has grabbed $18.4 million in venture backing to launch a startup biotech pursuing a pipeline of programs spun out of the pharma giant. Dr. Emiliangelo Ratti and Dr. Mike Trower gained the rights to a portfolio of clinical and preclinical neurokinin receptor antagonists divested from GSK for the newly coined NeRRe Therapeutics in London. In recent years GSK has cut back significantly on the neurosciences front, creating some opportunities for others to carry on the work. Novo and Advent Venture Partners are backing the upstart. Release